[1] is an international academic journal of the Australian and New Zealand Society for Immunology (ASI).

[2] In 2012, CTI was founded in direct response to a growing need for publishing clinically-orientated research papers in the field of immunology, including the latest advances in SARS-CoV-2 / COVID-19.

In 2018, CTI received its inaugural Impact Factor of 7.271 and is currently undergoing a rapid phase of significant growth, holding a ranking of 42/162 in the category of Immunology journals, according to 2020 Journal Citation Reports (Clarivate Analytics[3]).

CTI has a sister journal, Immunology & Cell Biology (ICB).

Each year, the ASI Annual Scientific Meeting hosts a dedicated workshop session to recognise the authors of top papers published in CTI and ICB.